APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal 13-valent Conjugate Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pneumococcal 13-valent Conjugate Vaccine Market Outlook and Growth Opportunities 2026

29 December 2025194 pages

Choose your research edition.

Industry ResearchPneumococcal 13-valent Conjugate Vaccine Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal 13-valent Conjugate Vaccine Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Pneumococcal 13-valent Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal 13-valent Conjugate Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal 13-valent Conjugate Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Pneumococcal 13-valent Conjugate Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pneumococcal 13-valent Conjugate Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pneumococcal 13-valent Conjugate Vaccine market include Pfizer, BIOKANGTAI and Walvax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumococcal 13-valent Conjugate Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal 13-valent Conjugate Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal 13-valent Conjugate Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumococcal 13-valent Conjugate Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal 13-valent Conjugate Vaccine Segment by Company

Pfizer

BIOKANGTAI

Walvax

Pneumococcal 13-valent Conjugate Vaccine Segment by Type

0.5ml

Other

Pneumococcal 13-valent Conjugate Vaccine Segment by Application

Hospital

Clinic

Pneumococcal 13-valent Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pneumococcal 13-valent Conjugate Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pneumococcal 13-valent Conjugate Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumococcal 13-valent Conjugate Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumococcal 13-valent Conjugate Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal 13-valent Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal 13-valent Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal 13-valent Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal 13-valent Conjugate Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal 13-valent Conjugate Vaccine industry.

Chapter 3: Detailed analysis of Pneumococcal 13-valent Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pneumococcal 13-valent Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pneumococcal 13-valent Conjugate Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal 13-valent Conjugate Vaccine Industry Trends Table 2. Pneumococcal 13-valent Conjugate Vaccine Industry Drivers Table 3. Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges Table 4. Pneumococcal 13-valent Conjugate Vaccine Industry Restraints Table 5. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Company (2021-2026) Table 7. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Pneumococcal 13-valent Conjugate Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pneumococcal 13-valent Conjugate Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pneumococcal 13-valent Conjugate Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Pneumococcal 13-valent Conjugate Vaccine Company, Product Type & Application Table 13. Global Pneumococcal 13-valent Conjugate Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumococcal 13-valent Conjugate Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 0.5ml Table 18. Significant Companies of Other Table 19. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Pneumococcal 13-valent Conjugate Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Pneumococcal 13-valent Conjugate Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 67. Pfizer Recent Development Table 68. BIOKANGTAI Company Information Table 69. BIOKANGTAI Business Overview Table 70. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 72. BIOKANGTAI Recent Development Table 73. Walvax Company Information Table 74. Walvax Business Overview Table 75. Walvax Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 77. Walvax Recent Development Table 78. Key Raw Materials Table 79. Raw Materials Key Suppliers Table 80. Pneumococcal 13-valent Conjugate Vaccine Distributors List Table 81. Pneumococcal 13-valent Conjugate Vaccine Customers List Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. Pneumococcal 13-valent Conjugate Vaccine Product Image Figure 2. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal 13-valent Conjugate Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Pneumococcal 13-valent Conjugate Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pneumococcal 13-valent Conjugate Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 0.5ml Image Figure 10. Other Image Figure 11. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Pneumococcal 13-valent Conjugate Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Pneumococcal 13-valent Conjugate Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 0.5ml
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Pfizer
  • BIOKANGTAI
  • Walvax

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pneumococcal 13-valent Conjugate Vaccine Market Dynamics
  1. 2.1 Pneumococcal 13-valent Conjugate Vaccine Industry Trends
  2. 2.2 Pneumococcal 13-valent Conjugate Vaccine Industry Drivers
  3. 2.3 Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal 13-valent Conjugate Vaccine Industry Restraints
3 Pneumococcal 13-valent Conjugate Vaccine Market by Company
  1. 3.1 Global Pneumococcal 13-valent Conjugate Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Pneumococcal 13-valent Conjugate Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Pneumococcal 13-valent Conjugate Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Pneumococcal 13-valent Conjugate Vaccine Company Product Type and Application
  8. 3.8 Global Pneumococcal 13-valent Conjugate Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pneumococcal 13-valent Conjugate Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pneumococcal 13-valent Conjugate Vaccine Market by Type
  1. 4.1 Pneumococcal 13-valent Conjugate Vaccine Type Introduction
  2. 4.1.1 0.5ml
  3. 4.1.2 Other
  4. 4.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Type
  5. 4.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Type
  9. 4.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type (2021-2032)
5 Pneumococcal 13-valent Conjugate Vaccine Market by Application
  1. 5.1 Pneumococcal 13-valent Conjugate Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Application
  5. 5.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Application
  9. 5.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application (2021-2032)
6 Pneumococcal 13-valent Conjugate Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Pneumococcal 13-valent Conjugate Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Country, 2025 VS 2032
7 Pneumococcal 13-valent Conjugate Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pneumococcal 13-valent Conjugate Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pneumococcal 13-valent Conjugate Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 BIOKANGTAI
  8. 8.2.1 BIOKANGTAI Company Information
  9. 8.2.2 BIOKANGTAI Business Overview
  10. 8.2.3 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  12. 8.2.5 BIOKANGTAI Recent Developments
  13. 8.3 Walvax
  14. 8.3.1 Walvax Company Information
  15. 8.3.2 Walvax Business Overview
  16. 8.3.3 Walvax Pneumococcal 13-valent Conjugate Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  18. 8.3.5 Walvax Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumococcal 13-valent Conjugate Vaccine Value Chain Analysis
  2. 9.1.1 Pneumococcal 13-valent Conjugate Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumococcal 13-valent Conjugate Vaccine Sales Mode & Process
  6. 9.2 Pneumococcal 13-valent Conjugate Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumococcal 13-valent Conjugate Vaccine Distributors
  9. 9.2.3 Pneumococcal 13-valent Conjugate Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst